Get in touch: 07730 619850

Birmingham LASER Information Event

An information event was held on Saturday 19th July 2014 at Heartlands Hospital MIDRU building in Birmingham for patients interested in taking part in the LASER trial.

The event was hosted by Dr. Adel Mansur and his asthma research team.

The day was a great success. Dr. Mansur started the day off with a talk about opportunities in research. He explained some of the potential benefits to patients in taking part in research and some of the opportunities locally for asthma patients in Birmingham.

We were very pleased to have D’Arcy Myers, Chief Executive of Allergy UK present and he gave an interesting talk about the work being done by Allergy UK and the services they have to support patients with allergy and asthma.

Dr. Will Storrar, Trial Coordinator for the LASER trial gave an overview of the trial and what taking part would involve for participants and Mr. Brian Jones gave a demonstration of the Airsonett TLA treatment device.

The day finished with a fantastic talk from one of Dr. Mansur’s patients about what it is like to be a patient taking part in research. It was a fascinating insight into what makes patients decide to take part in research and what, from a patients point of view, is important in making a decision about whether to take part.

We look forward to hearing about the progress at Birmingham as they start to screen patients for inclusion in the trial.

photo 5

The LASER event team (L-R) Heila Gharanei, Adel Mansur, Will Storrar, Tina Bettaney, Brian Jones.

photo 3

Dr. Adel Mansur describes research opportunities for patients with asthma.


Mr. D’Arcy Myers explains the work of Allergy UK

Leave a Reply

You must be logged in to post a comment.

Latest Tweets


The LASER trial team
Dept. of Respiratory Medicine
Level C, Queen Alexandra Hospital
Southwick Hill Road
Portsmouth, PO6 3LY

Get in touch

Contact the LASER Trial on 07730 619850, or by email

Keep up to date with what’'s happening at LASER trial by following us on Facebook and Twitter.